OXTERIL 350 VHP Biocide Authorized in the EU: What Manufacturers and Professional Users Must Do

Key data

Manufacturers, distributors and professional users of disinfectant products have a new mandatory regulatory reference as of 11 September 2026. The Commission Implementing Regulation (EU) 2026/2042 grants Union authorization for the biocide OXTERIL 350 VHP, a product based on hydrogen peroxide in vapor phase (VHP) intended for disinfection of surfaces and environments.

This authorization is not a minor formality: it means that the product has passed the efficacy and safety evaluation required by the Regulation (EU) 528/2012 on biocides, and that its commercialization and use are now subject to concrete and binding conditions throughout the EU.

What does this regulation establish?

Commission Implementing Regulation (EU) 2026/2042 grants a Union authorization for the OXTERIL 350 VHP biocide. This means that the product can be marketed and used in all EU Member States, but only under the conditions set out in the authorization itself.

The conditions established in the authorization include the following key elements:

• Use restrictions: the product may only be used for the expressly authorized uses, namely disinfection of surfaces and environments.
• Mandatory labeling: containers and commercial documentation must comply with the specific labeling requirements set out in the authorization.
• Protection measures: professional users must apply the safety and personal protection measures established in the authorization.
• Consequences of non-compliance: failure to comply with any of these conditions may result in withdrawal of authorization and the imposition of administrative sanctions.

VHP technology (Vapour Hydrogen Peroxide, hydrogen peroxide in vapor phase) is widely used in high microbiological demand environments, such as operating rooms, pharmaceutical clean rooms or food processing facilities. Union authorization facilitates its harmonized use throughout Europe, eliminating the need for separate national authorizations for this specific product.

Economic and operational impact

Union authorization for OXTERIL 350 VHP has a dual reading for companies in the sector:

• Commercial opportunity: manufacturers and distributors of the product gain direct access to the single European market without needing to obtain authorizations in each Member State. This reduces administrative costs and accelerates commercialization.
• Compliance obligation: authorization is not a blank check. Companies that already market or use OXTERIL 350 VHP must review that their processes, labels and usage protocols comply exactly with the conditions set out in Regulation 2026/2042. Any deviation is grounds for sanctions.

For professional users in sectors such as healthcare, food or pharmaceutical industry, the operational impact translates into the need to update disinfection protocols to ensure that the product is used only in authorized cases and that personnel apply the required protection measures.

The most relevant economic risk is not the cost of adaptation, but the cost of non-compliance: withdrawal of authorization would mean the inability to continue using or marketing the product, with the consequent impact on the supply chain and critical disinfection processes.

Who does it affect?

• OXTERIL 350 VHP manufacturers: must ensure that the product complies with all conditions of the authorization before commercialization.
• Distributors and marketers of biocides: must verify that the product labeling and documentation comply with the requirements of Regulation 2026/2042.
• Professional users in the healthcare sector: hospitals, clinics, laboratories and health centers that use OXTERIL 350 VHP in their disinfection protocols.
• Food industry: food processing, packaging and storage facilities where surface and environmental disinfection products are used.
• Pharmaceutical industry: manufacturers of medicines and health products that use VHP technology in clean rooms and controlled production areas.
• Procurement and safety managers in industrial companies: any company that includes OXTERIL 350 VHP in its list of approved disinfection products.

Practical example

A pharmaceutical laboratory that uses OXTERIL 350 VHP for disinfection of its clean rooms must, as of 11 September 2026, review its protocol for using the product. Specifically:

1. Verify that the use it makes of the product (disinfection of surfaces and environments) exactly matches the use authorized in Regulation 2026/2042.
2. Check that the containers of the product it has in stock comply with the labeling requirements of the new authorization. If the supplier has not yet updated the labels, it must request this.
3. Update standard operating procedures (SOPs) to include the personal protection measures required in the authorization.
4. Document these reviews to be able to prove them in a regulatory inspection.

If the laboratory does not perform these checks and an inspection detects non-compliant use or labeling, it exposes itself to withdrawal of the product authorization and administrative sanctions, which could paralyze its critical disinfection processes.

What should companies do now?

1. Identify if you use or market OXTERIL 350 VHP: review your catalog of disinfection products and confirm if this biocide is present in your operations.
2. Read the specific conditions of the authorization: access the full text of Commission Implementing Regulation (EU) 2026/2042 to know exactly the use restrictions, labeling requirements and protection measures required.
3. Review product labeling: if you are a manufacturer or distributor, ensure that the labels of all batches in circulation comply with the requirements of the new authorization.
4. Update internal usage protocols: if you are a professional user, adapt your disinfection procedures to the authorized conditions and train personnel in the required protection measures.
5. Document compliance: keep evidence of the reviews carried out (training records, updated versions of SOPs, communications with the supplier) to be able to prove it in an inspection.
6. Consult with a biocide regulation specialist if you have doubts about whether your specific use of the product is covered by the authorization or if you need to adapt any process.

Official source

Consult complete regulation in official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202602042